期刊
ERJ OPEN RESEARCH
卷 7, 期 2, 页码 -出版社
EUROPEAN RESPIRATORY SOC JOURNALS LTD
DOI: 10.1183/23120541.00425-2020
关键词
-
资金
- Novartis Pharma AG [QVM149B2209]
Once-daily inhaled IND/GLY/MF showed significant improvement in lung function and safety profile in patients with mild-moderate asthma, regardless of morning or evening dosing. The treatment demonstrated increased FEV1 and PEF over 14 days, with a safety profile comparable to placebo.
Once-daily asthma treatment should prevent night-time deterioration, irrespective of the time of dosing. IND/GLY/MF, a fixed-dose combination of inhaled indacaterol acetate (IND, long-acting beta 2-agonist (LABA)), glycopyrronium bromide (GLY, long-acting muscarinic antagonist) and mometasone furoate (MF, inhaled corticosteroid (ICS)) delivered by Breezhaler, is indicated in adult asthma patients inadequately controlled on LABA/ICS. A randomised, double-blind, placebo-controlled, three-period, crossover, phase II study was performed to investigate the bronchodilator effect of IND/GLY/MF (150/50/80 mu g) dosed morning and evening versus placebo in patients with mild-moderate asthma. The primary end-point was weighted mean forced expiratory volume in 1 s (FEV1) over 24 h following 14 days of IND/GLY/MF dosed a.m. and p.m. versus placebo. Secondary end-points included the effect of dosing time on peak expiratory flow (PEF) and safety/tolerability. Of 37 randomised patients (age 18-72 years; 21 male, 16 female) 34 completed all three treatment periods. At screening, median (range) pre-bronchodilator FEV1 was 75.8% (60-96%). Patients were using stable low(83.8%) or medium-dose (16.2%) ICS. Morning and evening dosing of IND/GLY/MF improved FEV1 (area under the curve from 0 to 24 h) by 610 mL (90% CI 538-681 mL) and 615 mL (90% CI 544-687 mL), respectively, versus placebo. Mean PEF over 14 days increased by 70.7 L.min(-1) (90% CI 60.5-80.9 L.min(-1)) following a.m. dosing, and by 59.7 L.min(-1) (90% CI 49.5-69.9 L.min-1) following p.m. dosing of IND/GLY/ MF versus placebo. IND/GLY/MF demonstrated a safety profile comparable with placebo. Once-daily inhaled IND/GLY/MF was well tolerated and provided sustained lung function improvements over 24 h, irrespective of a.m. or p.m. dosing, in patients with mild-moderate asthma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据